Alprolix (Coagulation factor IX [recombinant], Fc fusion protein) for Hemophilia

Overview
Alprolix is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with hemophilia B. Alprolix can also be used for perioperative (before, during, and after surgery) care and for routine prophylaxis. The technical name of Alprolix is Coagulation factor IX (recombinant), Fc fusion protein.

Alprolix is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Alprolix is given as an intravenous injection.

Alprolix comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Alprolix lists common side effects including headache and abnormal mouth sensations.

Rare but serious side effects listed for Alprolix include systemic allergic reactions and thromboembolic events.

For more details about this treatment, visit:

Alprolix.com

Treatment of Hemophilia – Hemophilia Federation of America